Voices of Biotech
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
Kai Pohlmeyer
August 1, 2013
1 Min Read
Richter-Helm has more than 25 years of experience in the development and good manufacturing practice (GMP)-compliant production of a wide range of biopharmaceuticals, including
recombinant proteins (e.g., cytokines, growth factors, antibody fragments, surface antigens)
plasmid DNA
microbial vaccines (e.g., attenuated whole cell vaccines).
Customized Solutions
Richter-Helm offers customized solutions for all steps in biopharmaceutical projects through contract development and manufacturing services featuring
Development of production strains (Escherichia coli, Pichia)
Establishment of MCB/WCB
Development of fermentation (1 to 1,500 L) and downstream processes
Development of analytical methods, including bioassay development
Validation of analytical methods
GMP manufacturing for clinical phase I to III
Commercial GMP manufacturing
Process validation
In-house quality control (QC) testing and release; stability studies according to ICH.
Out-Licensing
Richter-Helm out-licenses its own biosimilar developments in
women’s health (osteoporosis)
infectious diseases (hepatitis).
Active Pharmaceutical Ingredients
Sales of active pharmaceutical ingredients
Teriparatide
IFN alpha 2a.
Fill–Finish
We offer high-end fill and finish manufacturing services for injectables, production services for clinical and commercial batches.
About the Author
Author Details
Dr. Kai Pohlmeyer is head of business development, + 49-40-55 290-430; [email protected].
You May Also Like
Upcoming Webcasts
Jun 17 - Jun 20, 2024
Jun 17 - Jun 20, 2024
Our Biopharmaceutical School is the perfect course to gain a well-rounded understanding of the Biopharmaceutical industry. Over three days, you will understand the principle steps in the biopharmaceutical lifecycle, including: raw material selection, up and downstream processes and core technology. Additionally, you will be familiarised with the latest industry trends, including Industry 4.0, and how these are likely to impact the industry’s evolution.
Through a combination of sessions led by experts from the likes of GSK and Pall Biotech, as well as group discussions with your peers, you will learn how to bring a biopharmaceutical drug to market. Each day will be chaired by a different member of the BioProcess International Academy faculty and there will also be time for networking and Q&As with the experts.
Learn More